Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quinidine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EDP-305 and fluconazole interaction (Part 1) | EXPERIMENTAL | - |
| EDP-305 and quinidine interaction (Part 2) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fluconazole | DRUG | Subjects will receive fluconazole once daily from Day 5 to Day 18 |
| Quinidine | DRUG | Subjects will receive quinidine twice daily from Day 5 to Day 12 |
| EDP-305 | DRUG | Subjects will receive a single dose of EDP-305 on Day 1 and Day 14 |
Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive. * Female subjects must be of non-childbearing potential. Exclusion Criteria: * Clinically relevant evidence o...
Quinidine is an investigational small molecule being studied in the context of NASH, or nonalcoholic steatohepatitis. It has been evaluated in a Phase 1 clinical trial in healthy volunteers to assess drug-drug interactions. Quinidine is not approved for NASH and remains in clinical development.
Quinidine is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ENTA. The company is conducting clinical research on Quinidine in the metabolic therapeutic area, specifically related to NASH.
Quinidine is in Phase 1 clinical development. A Phase 1 trial has been completed, and there are no active trials currently listed. Quinidine is investigational and has not been approved by regulatory authorities for any indication.
Quinidine has one completed clinical trial, identified as NCT03610945. This was a Phase 1 drug-drug interaction study between EDP-305, fluconazole, and Quinidine in healthy volunteers. The trial enrolled 48 participants in the United States and was controlled but not randomized or double-blinded.
No, Quinidine is not the same as EDP-305. They are distinct compounds that were studied together in a clinical trial to evaluate drug-drug interactions. The trial, NCT03610945, assessed how these drugs interact when administered together in healthy volunteers.